Google
DMRA — DAMORA THERAPEUTICS, INC. (Healthcare >> Biotechnology)
DMRA FAQ
What is DMRA's ROE?
DAMORA THERAPEUTICS, INC. reports a Return on Equity (ROE) of -46.07%.
What is DMRA's dividend yield?
DAMORA THERAPEUTICS, INC. offers a dividend yield of 0.00%.
What is DMRA's Deepscope Quality Score?
Deepscope rates DMRA's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy DMRA?
Deepscope's AI Timing Score for DMRA is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does DMRA belong to?
DAMORA THERAPEUTICS, INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 21.01
Price
-1.30
(-5.83%)
Day Change
|
|
|---|
DMRA, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 78 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 21.01 |
| PBV / Sector |
2.69 / 4.63
|
| Earning Per Share | -3.59 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
8.23 M
|
| Average 1W Daily Value |
8.44 M
|
| Timing Factors |
|
14% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:23 |
| Symbol | DMRA |
| Name | DAMORA THERAPEUTICS, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 61.55 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,374.48 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Building 23, Waltham, MA, United States, 02453
Phone: 781 281 9020
Website: https://www.damoratx.com
Sector: Healthcare >> Biotechnology
Description: Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
